Freshly Printed - allow 10 days lead
Couldn't load pickup availability
Viral Vectors in Cancer Immunotherapy
Updates on virotherapy, a novel therapeutic strategy with great potential to enhance antitumor immune responses
Fernando Aranda Vega (Volume editor), Pedro Berraondo (Volume editor), Lorenzo Galluzzi (Volume editor)
9780443192494, Elsevier Science
Hardback, published 3 August 2023
274 pages
22.9 x 15.1 x 2.2 cm, 0.45 kg
Viral Vectors in Cancer Immunotherapy, Volume 379 in the International Review of Cell and Molecular Biology presents the latest on cancer immunotherapy and how it has transformed cancer treatment through advances in immune checkpoint inhibitors and adoptive cell therapy. Chapters in this new release include Past, present and future of viral vectors in cancer immunotherapy, Alphaviruses in cancer immunotherapy, Adenoviral-based cancer gene therapy, Armored modified vaccinia Ankara in cancer immunotherapy, Strategies of Semliki Forest virus in immuno-oncology, Maraba virus in cancer immunotherapy, Oncolytic viruses in hematological malignancies, Oncolytic virus for cancer therapies: Overview and future directions, and more. The use of genetically modified viruses allows the expression of pro-inflammatory molecules, while the immune system receives danger signals from the viruses themselves. In some cases, the virus can also induce tumor cell death. This book will review advances in virus-based cancer immunotherapy in both solid tumors and hematologic malignancies.
1. Viral Vectors Engineered for Gene Therapy Kenneth Lundstrom 2. Checkpoint blockade meets gene therapy: Opportunities to improve response and reduce toxicity Noelia Silva-Pilipich, Ángela Covo-Vergara, Lucía Vanrell, and Cristian Smerdou 3. Armored modified vaccinia Ankara in cancer immunotherapy Cigdem Atay, José Medina-Echeverz, Hubertus Hochrein, Mark Suter, and Maria Hinterberger 4. Alphaviruses in Cancer Immunotherapy Kenneth Lundstrom 5. Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical success Irati Hervás-Corpión and Marta M. Alonso 6. Oncolytic viruses in hematological malignancies: hijacking disease biology and fostering new promises for immune and cell-based therapies Mário Sousa-Pimenta, Ângelo Martins, and Vera Machado 7. Oncolytic virotherapy in lung cancer Estanislao Nistal-Villan, Sergio Rius-Rocabert, and Francisco Llinares-Pinel 8. Rational selection of an ideal oncolytic virus to address current limitations in clinical translation Rupsa Basu and Chad M. Moles
Subject Areas: Cellular biology [cytology PSF], Molecular biology [PSD], Developmental biology [PSC]
